Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
Authors
Keywords
-
Journal
DIGESTIVE DISEASES
Volume 29, Issue 3, Pages 289-302
Publisher
S. Karger AG
Online
2011-08-09
DOI
10.1159/000327562
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential Roles of Insulin-like Growth Factor Receptor- and Insulin Receptor-mediated Signaling in the Phenotypes of Hepatocellular Carcinoma Cells
- (2015) Ya-Wen Chen et al. NEOPLASIA
- Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
- (2011) Kazuomi Ueshima et al. DIGESTIVE DISEASES
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
- (2010) Masatoshi Kudo et al. ONCOLOGY
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
- (2009) S J Schoenleber et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
- (2009) T. Bekaii-Saab et al. CLINICAL CANCER RESEARCH
- Pathogenesis of hepatocellular carcinoma and molecular therapies
- (2009) Beatriz Mínguez et al. CURRENT OPINION IN GASTROENTEROLOGY
- mTOR inhibitors for hepatocellular cancer: a forward-moving target
- (2009) Gerhard Treiber Expert Review of Anticancer Therapy
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
- (2009) Jing-song Chen et al. HEPATOLOGY RESEARCH
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy
- (2009) Masatoshi Kudo JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Angiogenesis in liver disease
- (2009) Mercedes Fernández et al. JOURNAL OF HEPATOLOGY
- Sunitinib and the benefits of a negative study
- (2009) Alejandro Forner et al. LANCET ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- Targeted therapy for hepatocellular carcinoma
- (2009) Hans Christian Spangenberg et al. Nature Reviews Gastroenterology & Hepatology
- Epidermal Growth Factor Receptor Expression and Gene Copy Number in Conventional Hepatocellular Carcinoma
- (2008) Anne F. Buckley et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy
- (2008) Masatoshi Kudo ONCOLOGY
- Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
- (2008) Michael Höpfner et al. WORLD JOURNAL OF GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started